Last updated: June 30, 2026

Norethin 1/35E-28 Market Dynamics and Financial Trajectory (Revenue, Pricing, Competition, Exclusivity, and IP Risk)

Executive summary: Norethin 1/35E-28 is an oral contraceptive (ethinyl estradiol 35 mcg plus norethindrone acetate 1 mg; “28” day pack). Public market data tied to this exact proprietary listing (sales, channel mix, pharmacy contracts) is not available in a way that supports an accurate, point-in-time financial trajectory at the product level. The commercial outlook is instead determined by: (1) generic substitution risk within oral contraceptives, (2) payer-driven price compression, (3) wholesaler channel norms for high-volume generics, (4) patent and exclusivity posture that constrains or enables generics, and (5) FDA labeling continuity across equivalent strengths and dosing regimens. For business planning, the market behaves as a low-differentiation, high-substitutability class where branded unit economics typically trend toward erosion after generic entry or after exclusivity lapses.

What is Norethin 1/35E-28 and how is it positioned in the oral contraceptive market?

Featured snippet: Norethin 1/35E-28 is an oral contraceptive combination product (ethinyl estradiol + norethindrone acetate) dispensed in a 28-day regimen.

Core commercial attributes

Drug class: Combined oral contraceptive (COC)
Active ingredients (label strength):
- Ethinyl estradiol: 35 mcg
- Norethindrone acetate: 1 mg
Regimen: 28-day pack (commonly 21 active + 7 placebo days or equivalent schedule depending on labeling)
Therapeutic use: Contraception; labeling also often includes cycle-related benefits depending on the brand’s approved indications and usage language.

Market structure for COCs

Oral contraceptives in the US typically follow:

High generic penetration and rapid payer switching.
Strong PBM formulary pressure toward lowest net cost.
Limited clinical differentiation among therapeutically equivalent COCs at the molecule-and-strength level.
High substitution at the pharmacy counter if the product is not on a restrictive dispense position.

How competitive is the Norethin 1/35E-28 oral contraceptive segment?

Featured snippet: COC competition is dominated by multiple generic versions of similar ethinyl estradiol/norethindrone acetate strengths and pack regimens, with pricing driven by net cost and formulary status.

Substitutability and switching dynamics

Switching is facilitated by:
- Therapeutic equivalence for the contraceptive indication.
- Physician and patient tolerance for multiple equivalent COCs.
- Retail and mail channel stocking practices for generic COCs.
Competitive pressure increases when:
- A branded product loses exclusivity (or has weak patent coverage) and generics enter.
- PBMs narrow coverage to a small formulary “preferred” list.
- Patient cost-sharing rises for non-preferred brands.

Competitive metrics that typically matter

For COCs, the practical KPIs are less “clinical performance” and more:

Net price and contract status with PBMs and major GPOs.
Dispense share in retail and mail.
Patient persistence (continuation rates) which determines whether any brand retains volume after substitution.
NDC-level availability and supply reliability, which can drive temporary share shifts.

When does Norethin 1/35E-28 face exclusivity loss or generic launch risk?

Featured snippet: Exclusivity and patent expiry determine whether Norethin 1/35E-28 can block generic entry. Without a product-specific Orange Book record and identified listed patents, timing cannot be stated with required precision.

What governs timing in US COCs

For combination oral contraceptives, generic launch timing depends on:

Listed Orange Book patents (drug substance and drug product formulation patents, if any; and method-of-use patents if present).
Patent term adjustment and patent-specific expiration.
Patent expiration vs. market exclusivity, including:
- Hatch-Waxman 5-year/3-year exclusivity patterns tied to NDA category at approval (if applicable).
- Any relevant pediatric exclusivity (6-month extension) tied to the NDA or relevant patents.
Paragraph IV filings that can trigger 180-day generic exclusivity.

Practical interpretation for business

Because the segment is highly substituted, the commercial impact usually occurs rapidly after:

The first strong generic entrant gains preferential positioning, or
A bioequivalent generic captures meaningful retail share.

What is the Orange Book status of Norethin 1/35E-28 and which patents are listed?

Featured snippet: Orange Book status is the controlling source for listed patents tied to the specific NDC and NDA. A complete, accurate patent list cannot be provided here without the specific Orange Book listing identifiers for Norethin 1/35E-28.

How to read the patent estate for this product type

COCs typically have:

Drug product/formulation patents (sometimes weak for straightforward combination tablets unless a specific technology is claimed).
Method-of-use patents (less common for “plain contraception” but can occur for specific dosing regimens or therapeutic schedules).
Process patents (often not enforceable against generics if not practiced by the ANDA applicant’s manufacturing).

Business implication

If the Orange Book estate is limited to broad drug-product claims or if claims are not well aligned with ANDA manufacturing, litigation and enforceability are usually lower than perceived. For investors and licensors, the decisive issue is claim scope versus generic manufacturing and whether there are multiple, staggered, enforceable patents.

How strong is the patent estate for Norethin 1/35E-28?

Featured snippet: The strength of a COC’s patent estate is determined by listed patent count, remaining term, claim breadth, and the likelihood that ANDA manufacturing design-arounds avoid infringement. A precise assessment cannot be produced without the identified listed patents and remaining expirations.

What “strong” typically means in practice

Multiple independent claims that directly map to core ANDA activities.
Remaining term across several years (staggered expirations).
Clear infringement theories that are hard to design around.
Litigation history showing enforceability or consistent settlements.

What “weak” typically looks like

Few listed patents with short remaining term.
Claims that are easy to design around (e.g., non-critical formulation elements).
Lack of credible exclusivity enforcement in prior COC disputes.

What patent litigation and Paragraph IV challenges affect Norethin 1/35E-28?

Featured snippet: Paragraph IV disputes can drive a branded COC’s revenue trajectory by delaying or accelerating generic entry. Specific Norethin 1/35E-28 litigation details cannot be listed here without case-level records tied to the exact ANDA/NDA.

How litigation typically impacts a COC

Settlements often establish:
- “Designated” launch dates for generic entry.
- Market share agreements or supply arrangements in some cases.
- Carve-outs for additional strengths or dosage forms.
Even without litigation, unapproved pricing pressure and PBM switching often dominate after generic entry.

How does Norethin 1/35E-28 compare with competing norethindrone acetate/ethinyl estradiol COCs?

Featured snippet: Competitive COCs in the same strength class (ethinyl estradiol 35 mcg + norethindrone acetate 1 mg) are near substitutes, so price and formulary status typically drive share.

Comparison dimensions that usually move share

Formulary position: preferred vs non-preferred tiers.
Net price and rebates: PBM-driven economics.
Patient out-of-pocket: copay and cost-sharing design.
Supply stability: in high-volume generics, shortages can temporarily disrupt.
Dispense configuration: 28-day pack availability and NDC continuity.

Outcome for revenue trajectory

If Norethin 1/35E-28 is branded in a market where equivalent generics exist, its financial trajectory usually shows:

Share decline after generic availability.
Margin compression from rebates to retain placement.
Periodic stabilization if formulary positions are maintained, followed by step-down upon preferred switch to lower-cost competitors.

What are the regulatory dynamics for Norethin 1/35E-28 (FDA status, ANDA pathway, and interchangeability)?

Featured snippet: For COCs, most generic entry uses the ANDA pathway with bioequivalence to a reference listed drug; regulatory status affects substitution, not therapeutic effect.

FDA pathway implications

If Norethin 1/35E-28 is the reference for a given generic, substitution relies on:
- ANDA approval and labeling.
- Pharmacy-level switch rules.
- State-level substitution laws and labeling language.
Interchangeability is generally not the differentiator for COCs as it is in biologics; rather, it is “pharmaceutically equivalent” substitution and PBM position.

What is the commercial financial trajectory pattern for COCs like Norethin 1/35E-28 after generic entry?

Featured snippet: Revenue typically declines quickly after generic entry; branded products often shift from volume-growth to value-preservation via contracts, rebates, and targeted payer segments.

Typical financial trajectory shape (industry pattern for branded oral contraceptives)

While product-specific revenue and net sales for Norethin 1/35E-28 are not available here in a verifiable form, the expected pattern in mature COC markets is:

Pre-generic / protected period: stable share and higher price.
First generic entry: rapid unit decline, immediate price competition, and tighter PBM rebate leverage.
After 180 days and subsequent entrants: accelerated share erosion as additional generics reach formulary.
Late-stage maturity: revenue becomes small relative to category size, and the brand’s role becomes mainly contractual or niche.

Drivers of deviations from the “typical” pattern

Strong payer contracts that keep “brand-only” logic in place for certain members.
Limited generic availability at a given NDC or supply constraints.
Differential pack labeling and patient adherence support that PBMs pay to maintain (rare for plain COCs).

What generic entry risks exist for Norethin 1/35E-28?

Featured snippet: The dominant generic entry risk is standard ANDA approval for equivalent COCs; the timing and whether entry is blocked depends on the Orange Book patent estate and litigation/settlement outcomes.

Entry risk vectors

ANDA approvals for ethinyl estradiol 35 mcg + norethindrone acetate 1 mg tablets.
Design-around strategies that avoid infringement of specific formulation or method claims.
Market exclusivity barriers, including any triggered exclusivity if multiple Paragraph IV filings occur.

Commercial risk

Even if patents delay the first generic entrant, category dynamics still pressure branded economics through:

PBM formulary re-tiering.
Mandatory switching edits and step therapy behavior.
Patient copay differentials that drive pharmacy substitution.

How should licensing, investment, or litigation decisions be framed for Norethin 1/35E-28?

Featured snippet: For mature COCs, deal terms usually hinge on enforceable, claim-specific patent value and the probability of generic design-around, not on broad platform claims.

Actionable decision points (what matters most)

Patent-to-manufacturing mapping: whether listed claims read on generic tablets at the NDC level.
Remaining claim life: calendar value must exceed the time needed to litigate and launch.
Settlement likelihood: in COCs, settlements are common once generic entry is inevitable and enforceability is uncertain.
Formulary economics: even a delayed launch can underperform expectations if PBMs pre-position generic alternatives.

Key Takeaways

Norethin 1/35E-28 is a combined oral contraceptive (ethinyl estradiol 35 mcg + norethindrone acetate 1 mg) in a 28-day regimen, competing in a highly substitutable, generic-heavy category.
The market’s financial trajectory is driven primarily by generic substitution, PBM formulary status, net pricing/rebates, and supply continuity rather than clinical differentiation.
Exclusivity timing, patent expiration, and litigation outcomes are the decisive determinants of whether branded revenue persists or collapses after generic entry, but a precise Norethin 1/35E-28 patent-and-timeline view cannot be stated here without the product-specific Orange Book listing and listed patent identifiers.

FAQs

Does Norethin 1/35E-28 have OTC substitution or pharmacy switch rules that affect demand?
How do PBM formulary tier changes typically impact unit share for branded COCs like Norethin?
What is the typical net price compression timeline after generic entry in ethinyl estradiol/norethindrone acetate strengths?
How do settlement agreements in COC Paragraph IV cases usually structure launch dates?
What manufacturing/IP design-arounds most commonly neutralize COC formulation patents in ANDAs?

References

FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (accessed 2026-06-30).
FDA “Hatch-Waxman” framework and ANDA regulatory pathway guidance (FDA resources; accessed 2026-06-30).
FDA bioequivalence and generic approval resources for ANDAs (accessed 2026-06-30).

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Patent Applications:	219
DailyMed Link:	NORETHIN 1/35E-28 at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	NORETHIN 1/35E-28	ethinyl estradiol; norethindrone	TABLET;ORAL-28	071481-001	Apr 12, 1988		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for NORETHIN 1/35E-28